However, given the low, but significantly increased risk of gastrointestinal perforation in other large studies evaluating IL-6/IL-6R blockers in rheumatologic diseases, such as tocilizumab [33], patients with a history of gastrointestinal perforation, diverticulitis, or inflammatory bowel disease will not be included in the present trial. Here, IL6 is linked to diverticulitis.